Both Seattle and Pieris have been busy on the deal front, and today their lists grew longer as the two pair on developing immuno-oncology treatments.
Syndesi begins life with a $20.9 million infusion, to carry a SV2A modulator through early proof of concept.
Theravance will bring its GI drug through phase 2/3 in Crohn's disease and ulcerative colitis.
Celltex Therapeutics and Texas A&M Institute for Regenerative Medicine hope to have a stem cell-derived therapy for Alzheimer’s within three years.
Chinese biotech NetVation DL Medicine has arrived on the scene with a two-year alliance with Pfizer, plus an equity investment from the big pharma group.
Voyager Therapeutics’ chief and founder Steven Paul, M.D., is stepping down to become an “executive science advisor.”
Warp Drive has been working to live up to its name, speeding through development and deals.
After a deal for Immunomedics fell through last May, Seattle Genetics has scaled down spending to ink a $614 million deal for Cascadian Therapeutics.
Vical, hit with trial flop after trial flop—including a cytomegalovirus vaccine licensed from Astellas—is letting go of around half of its workforce.
BridgeBio will develop the drug for FGFR-related diseases, including bile duct cancer and a form of dwarfism.